Cell therapy (NK cells) · Kills target cells, directed at MICA and MICB · developed by Fate Therapeutics
FT536 is an allogeneic, off-the-shelf natural killer cell therapy derived from a clonal induced pluripotent stem cell line and engineered to express a chimeric antigen receptor targeting the alpha 3 domain of MICA and MICB, a high-affinity non-cleavable CD16 receptor, and an IL-15/IL-15 receptor alpha fusion, with CD38 knocked out. It kills MICA/B-expressing tumor cells and is studied in astrocytoma and glioblastoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07560865 | Phase 1 | Astrocytoma | Recruiting | FATE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
AstrocytomaGlioblastomaProgressive Disease
Updated Nov 15, 2026. Something wrong or missing? Report it on the FATE page.
See FATE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
FATE catalysts and pipeline →